Last reviewed · How we verify
Split virion, inactivated Influenza vaccine — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
Split virion, inactivated Influenza vaccine (Split virion, inactivated Influenza vaccine) — Sanofi Pasteur, a Sanofi Company.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Split virion, inactivated Influenza vaccine TARGET | Split virion, inactivated Influenza vaccine | Sanofi Pasteur, a Sanofi Company | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Split virion, inactivated Influenza vaccine CI watch — RSS
- Split virion, inactivated Influenza vaccine CI watch — Atom
- Split virion, inactivated Influenza vaccine CI watch — JSON
- Split virion, inactivated Influenza vaccine alone — RSS
Cite this brief
Drug Landscape (2026). Split virion, inactivated Influenza vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/split-virion-inactivated-influenza-vaccine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab